Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold_老虎社区_美港股上老虎

Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold

Benzinga2021-11-26

The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.). The FDA plans to ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Chillman
·2021-11-26
Ok
回复
1
举报
收起
- kaite:
  ok
  2021-11-26
  回复
  举报
Jen88
·2021-11-26
Ok
回复
2
举报
收起
- Chillman:
  Ok
  2021-11-26
  回复
  举报
Yappydappy
·2021-11-26
Sian
回复
3
举报
收起
- Jen88:
  Ok
  2021-11-26
  回复
  举报
Never ever f
·2021-11-26
Omg
回复
1
举报
收起
- starry123:
  lol
  2021-11-26
  回复
  举报
- Yappydappy:
  Sigh
  2021-11-26
  回复
  举报
Cfgramos
·2021-11-26
That’s gonna hurt
回复
1
举报
收起
- Never ever f:
  Very hurt
  2021-11-26
  回复
  举报
LplMichelle
·2021-11-26
Sure
回复
3
举报
LplMichelle
·2021-11-26
Pls like
回复
2
举报
收起
- RChia:
  LikE
  2021-11-26
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1136453460?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-26 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136453460","market":"us","top_or_hot":-1,"title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","media":"Benzinga","content":"<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","article_id":"1136453460","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","pubTimestamp":1637933775,"columns":[],"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"在关键的新冠肺炎疫苗试验被美国食品和药物管理局搁置后，Ocugen股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":877283354,"gmtCreate":1637935775242,"gmtModify":1637935775393,"author":{"id":"3558275010133966","authorId":"3558275010133966","name":"Chillman","avatar":"https://static.tigerbbs.com/26d692768260a0369516e9c9a49897ec","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3558275010133966","authorIdStr":"3558275010133966"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877283354","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","kind":"news","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6736960,"gmtCreate":1637941971493,"gmtModify":1637941971547,"authorId":3583188574218530,"author":{"id":3583188574218530,"idStr":"3583188574218530","authorId":3583188574218530,"name":"kaite","avatar":"https://static.tigerbbs.com/40a7ccc0fdb94090d52b243148991f8a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877283354,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":877289506,"gmtCreate":1637935724761,"gmtModify":1637935729699,"author":{"id":"3582993517958198","authorId":"3582993517958198","name":"Jen88","avatar":"https://static.tigerbbs.com/5aaf732b230f1241c2c9b76b2b27ae00","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582993517958198","authorIdStr":"3582993517958198"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877289506","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","kind":"news","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6735296,"gmtCreate":1637935782408,"gmtModify":1637935782439,"authorId":3558275010133966,"author":{"id":3558275010133966,"idStr":"3558275010133966","authorId":3558275010133966,"name":"Chillman","avatar":"https://static.tigerbbs.com/26d692768260a0369516e9c9a49897ec","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877289506,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":877289984,"gmtCreate":1637935630854,"gmtModify":1637935631049,"author":{"id":"3579410204959880","authorId":"3579410204959880","name":"Yappydappy","avatar":"https://static.tigerbbs.com/5b6252f503d56d09093797f9e318ebf9","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3579410204959880","authorIdStr":"3579410204959880"},"htmlText":"Sian","listText":"Sian","text":"Sian","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877289984","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","kind":"news","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6735285,"gmtCreate":1637935720387,"gmtModify":1637935720487,"authorId":3582993517958198,"author":{"id":3582993517958198,"idStr":"3582993517958198","authorId":3582993517958198,"name":"Jen88","avatar":"https://static.tigerbbs.com/5aaf732b230f1241c2c9b76b2b27ae00","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877289984,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":877212504,"gmtCreate":1637935294425,"gmtModify":1637935294780,"author":{"id":"3555043402922696","authorId":"3555043402922696","name":"Never ever f","avatar":"https://static.tigerbbs.com/52501d43721648c944a019db9c767c5d","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3555043402922696","authorIdStr":"3555043402922696"},"htmlText":"Omg&nbsp;","listText":"Omg&nbsp;","text":"Omg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/877212504","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","kind":"news","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6735290,"gmtCreate":1637935761176,"gmtModify":1637935761280,"authorId":3574823700698255,"author":{"id":3574823700698255,"idStr":"3574823700698255","authorId":3574823700698255,"name":"starry123","avatar":"https://static.tigerbbs.com/87d54ddf9f429d363c691c937e6c97a4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877212504,"type":1,"supId":6735269,"prevId":0,"content":"<u>lol</u>","text":"<u>lol</u>","html":"<u>lol</u>"},{"id":6735269,"gmtCreate":1637935622005,"gmtModify":1637935622034,"authorId":3579410204959880,"author":{"id":3579410204959880,"idStr":"3579410204959880","authorId":3579410204959880,"name":"Yappydappy","avatar":"https://static.tigerbbs.com/5b6252f503d56d09093797f9e318ebf9","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877212504,"type":1,"supId":0,"prevId":0,"content":"Sigh","text":"Sigh","html":"Sigh"}],"langContent":"CN"},{"id":877218487,"gmtCreate":1637935162172,"gmtModify":1637935162384,"author":{"id":"3577318628836449","authorId":"3577318628836449","name":"Cfgramos","avatar":"https://static.tigerbbs.com/8e4f5dee285970cb0d50c61a4302a33f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577318628836449","authorIdStr":"3577318628836449"},"htmlText":"That’s gonna hurt","listText":"That’s gonna hurt","text":"That’s gonna hurt","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877218487","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","kind":"news","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6735213,"gmtCreate":1637935302466,"gmtModify":1637935302501,"authorId":3555043402922696,"author":{"id":3555043402922696,"idStr":"3555043402922696","authorId":3555043402922696,"name":"Never ever f","avatar":"https://static.tigerbbs.com/52501d43721648c944a019db9c767c5d","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877218487,"type":1,"supId":0,"prevId":0,"content":"Very hurt ","text":"Very hurt ","html":"Very hurt "}],"langContent":"CN"},{"id":877236626,"gmtCreate":1637934029218,"gmtModify":1637934029431,"author":{"id":"3582025954833628","authorId":"3582025954833628","name":"LplMichelle","avatar":"https://static.tigerbbs.com/f3f2fe5070ffb7507fcc119e4bce015e","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582025954833628","authorIdStr":"3582025954833628"},"htmlText":"Sure","listText":"Sure","text":"Sure","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877236626","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","kind":"news","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":877236088,"gmtCreate":1637933982721,"gmtModify":1637933982902,"author":{"id":"3582025954833628","authorId":"3582025954833628","name":"LplMichelle","avatar":"https://static.tigerbbs.com/f3f2fe5070ffb7507fcc119e4bce015e","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582025954833628","authorIdStr":"3582025954833628"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877236088","repostId":1136453460,"repostType":4,"repost":{"id":"1136453460","kind":"news","pubTimestamp":1637933775,"share":"https://www.laohu8.com/m/news/1136453460?lang=&edition=full","pubTime":"2021-11-26 21:36","market":"us","language":"en","title":"Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453460","media":"Benzinga","summary":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to eva","content":"<p>The&nbsp;FDA has issued a clinical hold&nbsp;on&nbsp;<b>Ocugen Inc's</b>&nbsp;Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).</p>\n<ul>\n <li>The FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.</li>\n <li>The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.</li>\n <li>BBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.</li>\n <li>Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</li>\n <li><b>Price Action:</b>&nbsp;OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24302992/ocugen-shares-fall-after-its-pivotal-covid-19-vaccine-trial-put-on-fda-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453460","content_text":"The FDA has issued a clinical hold on Ocugen Inc's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152 (known as Covaxin outside the U.S.).\n\nThe FDA plans to identify the specific deficiencies that are the basis for clinical hold and information on addressing those deficiencies.\nThe Company expects to receive formal written communication with the additional information from the FDA and plans to work with the agency to resolve its questions as promptly as possible.\nBBV152 is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology.\nCovaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.\nPrice Action: OCGN shares are down 16% at $5.94 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6735006,"gmtCreate":1637934270843,"gmtModify":1637934270877,"authorId":3576295472948618,"author":{"id":3576295472948618,"idStr":"3576295472948618","authorId":3576295472948618,"name":"RChia","avatar":"https://static.tigerbbs.com/cea89db323c5328650526772cf80ec19","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":877236088,"type":1,"supId":0,"prevId":0,"content":"LikE","text":"LikE","html":"LikE"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":73,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}